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Immune checkpoint inhibitors have emerged as a promising new 
class of anti-cancer drugs. Unfortunately, while potentiating the 
immune system’s response to cancer cells, these drugs also 
place the patient at risk for the development of immune-related 
adverse events (irAEs). Most often, the gastrointestinal tract and 
skin are involved. However, involvement of the endocrine 
system also occurs. While thyroid dysfunction is the most 
common endocrinological irAE, hypophysitis is also frequently 
seen - and is especially associated with ipilimumab (1). 
Case Presentation Conclusion
A 60-year-old male undergoing combination immune checkpoint 
therapy with nivolumab (an anti-PD-1 antibody) and ipilimumab 
(an anti-CTLA-4 antibody) for metastatic melanoma developed 
headaches. An MRI of the brain was obtained and 
demonstrated new enlargement of the pituitary. 
Initial differential considerations included a metastatic lesion to 
the pituitary stalk, however the patient was also found to be 
hypothyroid. Further endocrinological evaluation revealed low 
testosterone, low random cortisol level, and low TSH, 
consistent with pituitary insufficiency. 
For management, checkpoint inhibitor therapy was held and the 
patient was treated with prednisone 1mg/kg for 2 weeks, with 
excellent clinical response, including resolved headaches and 
improved energy. Follow-up MRI demonstrated resolution of the 
pituitary enlargement.
Following resolution of initial symptoms, this patient was initially 
resumed on single agent nivolumab, however due to 
progression of disease was changed to trametinib (MEK 
inhibitor antibody) and dabrafenib (BRAF inhibitor antibody) for 
targeted BRAF mutated melanoma. At the time of this report, 
the patient has had recurrence hypothyroidism and is 
undergoing repeat endocrinological evaluation for recurrent 
hypopituitarism.
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As new cancer therapies emerge, physicians must remain aware 
of the potential for unique adverse effects – such as those 
occurring with immune checkpoint inhibitor therapies, including 
hypophysitis. As the imaging appearance of hypophysitis is not 
specific, understanding the clinical context in which it occurs can 
aid radiologists in recognizing it as a possible diagnosis and help 
guide appropriate clinical management.
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CTLA-4 and PD1 are immune-checkpoint proteins involved in the 
regulation of T-cell proliferation. Inhibition of these proteins 
results in increased T-cell activation, which has shown positive 
effects on the treatment of melanoma, although the mechanism 
is not known (4). However, decreased regulation of T-cell 
activation leads to less specific immune activity, which results in 
immune-related adverse events (1).
Of these, panhypopituitarism can be one of the most profound. 
Symptoms of combination immune checkpoint inhibitor therapy 
induced autoimmune hypophysitis are variable and can include 
headache, fatigue, hypopituitarism, and/or hyponatremia, as 
were seen in this patient. Vision changes and other 
endocrinopathies, such as type 1 diabetes and diabetes 
insipidus, can also be seen, although was not present in this 
case (2,5).
While hypophysitis can occur with ipilimumab alone  (up to 17% 
incidence), frequency and severity is greater when combined 
with nivolumab (5). Treatment consists of discontinuation, 
corticosteroids, and hormone replacement.  Recovery of 
hormone function, particularly of corticotrophins, is variable (1). 
Sagittal pre-contrast MR images demonstrate a normal 
appearance of the pituitary prior to initiation of the combination 
checkpoint inhibitor therapy (A) and interval enlargement of the 
pituitary approximately three months later near the end of the 
combination therapy (B) with predominantly homogeneous 
enhancement (D). A sagittal post-contrast T1 MR image following 
checkpoint inhi0bitor therapy discontinuation and steroid 
treatment demonstrates near resolution of the pituitary 
enlargement (C) and symmetric enhancement (E).
This pattern of symmetric enhancement of the pituitary stalk with 
resolution is characteristic of ipilimumab associated autoimmune 
hypophysitis, but it is not specific (2,3).
Goals and Objectives
1. Describe a case of immune-checkpoint inhibitor-induced 
hypophysitis in a patient on combination immune checkpoint 
inhibitor therapy for metastatic melanoma.
2. Discuss the imaging findings of autoimmune hypophysitis 
associated with immune checkpoint inhibitors.
3. Familiarize the audience with the occurrence of this rare 
complication of a novel therapy, so that it may be more 
readily recognized.
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